SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-ST-01(NCT04581473). This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Cla ...

Avis Budget Group, Inc. (CAR) is benefiting from strong car rental demand, strategic fleet management, technology investments, and share buybacks, boosting profitability and investor confidence. The Zacks Consensus Estimate for the company’s 2025 earnings is 1.38 per share, indicating an 182% year-over-year increase.The car rental industry, particularly in North America, has been experiencing strong demand driven by changes in consumer behavior, including an emphasis on short-term vehicle access rather than ...

Autolus Therapeutics plc (NASDAQ: AUTL ) is a promising CAR T-cell biotech that recently received FDA approval for AUCATZYL. This is AUTL's main value driver, and it's indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia [ALL]. Based onMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate ...

– Mercedes-Benz's elegant midsize luxury car has outdone its competitors to secure MotorTrend's Golden Calipers for the second time in five years –LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- MotorTrend Group, a Warner Bros. Discovery company, announced today the Mercedes-Benz E-Class as its 2025 Car of the Year award winner. The new E-Class, available as both a sedan and wagon-crossover, claimed the top spot amongst competitors for its elegant, refreshed design, excellent performance, and technology. MOT ...

Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.Data were presented at the American College of Rheumatology 2024.Also Read: Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee IssueCC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell therapy that expresses ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being cond ...

27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819; Favorable Safety Profile with No Grade ≥3 Adverse Events and No Events of CRS, ICANS, or GvHD Reconstituted B Cell Compartment Predominantly Consists of Naïve, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells and Plasmablas ...

Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncologyAdvancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumorsVirtual R&D Day featuring partner Astellas Pharma and Poseida's lead ...

Avis Budget Group, Inc. (CAR) reported lower-than-expected third-quarter 2024 results.See Zacks Earnings Calendar to stay ahead of market-making news.Despite the earnings miss, the stock has gained 12% since the earnings release on Oct. 31, 2024.CAR’s earnings of $6.7 per share missed the Zacks Consensus Estimate by 22.2% and decreased 60.4% from the year-ago quarter’s actual. Total revenues of $3.5 billion missed the consensus estimate by 2.3% and declined 2.4% on a year-over-year basis.Avis Budget’s share ...

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in Phase 1 Solid Tumor Study Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State at Day 8 Following Treatment SAN DIEGO, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company ...